Talcum Powder Lawsuit in Illinois

Yes. More than 63,000 lawsuits have been filed against Johnson & Johnson alleging that Baby Powder and other talc-based products caused ovarian cancer and mesothelioma. You may have a legal claim if you used J&J talcum powder products and were subsequently diagnosed with ovarian cancer, mesothelioma, fallopian tube cancer, peritoneal cancer, or endometrial cancer. The strongest claims involve long-term perineal use with a documented cancer diagnosis. Attorneys handle these cases on contingency. Fee arrangements vary, so confirm terms with any attorney you consult. The MDL 2738 in the District of New Jersey is actively coordinating thousands of federal cases, and state court proceedings continue nationwide.

The FDA’s 2019 testing detected chrysotile asbestos in J&J Baby Powder samples. Chrysotile is the most common form of asbestos, accounting for approximately 95% of asbestos used commercially. J&J’s internal documents also reference contamination by tremolite and anthophyllite asbestos fibers — amphibole asbestos types that are particularly associated with mesothelioma risk. All forms of asbestos are classified as Group 1 carcinogens by the IARC, meaning there is sufficient evidence they cause cancer in humans. There is no safe level of exposure to any type of asbestos.

Johnson & Johnson discontinued talc-based Baby Powder in North America in May 2020 and globally in August 2022. The current Baby Powder product sold by J&J uses cornstarch instead of talc. However, other companies continue to sell talc-based body powders, and many consumers used talc-based Baby Powder for years or decades before the discontinuation. The fact that J&J no longer sells talc-based Baby Powder does not affect legal claims based on past use of the talc-based product. If you used talc-based Baby Powder in the past and were diagnosed with cancer, your claim is based on the product you used, not the product currently on shelves.

The individuals who have standing to file a wrongful death claim vary by state but typically include the surviving spouse, adult children, parents of minor children, and in some states, other close family members or dependents. In most jurisdictions, the claim is filed by the personal representative of the deceased’s estate on behalf of all eligible survivors. If your loved one died from ovarian cancer or mesothelioma and used J&J talcum powder products, multiple family members may be eligible to pursue a claim. An attorney can evaluate your state’s wrongful death statute and determine who has standing and what damages are available.

The Third Circuit Court of Appeals rejected LTL Management’s bankruptcy petition because the filing was not made in good faith. The court found that LTL was not in genuine financial distress — it was a shell entity created by J&J solely to absorb talc liabilities and file for bankruptcy protection. J&J, with approximately $400 billion in market capitalization, had the financial capacity to pay talc claims through the normal litigation process. The court ruled that allowing profitable companies to create shell entities for the purpose of shielding themselves from legitimate tort claims would undermine the entire bankruptcy system. The ruling was upheld in 2025 when LTL attempted a second filing.

Asbestos and talc are minerals that naturally co-occur in geological formations. When talc is mined, asbestos fibers — including tremolite, anthophyllite, and chrysotile — can contaminate the talc if the mining operation does not adequately test for and remove these fibers. J&J’s talc was sourced from mines where asbestos was present in the surrounding rock. Internal J&J documents from the 1970s show the company was aware that its talc contained asbestos contamination. The FDA confirmed the presence of chrysotile asbestos in J&J Baby Powder samples through independent testing in October 2019. Despite this knowledge, J&J continued selling talc-based Baby Powder for decades without adequate testing or consumer warnings.

The evidence linking perineal talcum powder use to ovarian cancer is substantial and has been accumulating for over four decades. The 1982 Cramer et al. study found an odds ratio of 1.92, and subsequent studies — including large prospective cohort studies like the Harvard Nurses’ Health Study — have consistently confirmed a positive association with hazard ratios typically ranging from 1.20 to 1.40. The IARC upgraded talc to Group 2A ("probably carcinogenic") in July 2024 based on the totality of epidemiological, animal, and mechanistic evidence. Talc particles have been found embedded in ovarian tumors, confirming the migration pathway. The evidence is strong enough that juries across the country have returned billions in verdicts, and J&J discontinued talc-based Baby Powder.

There is no single "average" talcum powder settlement because values vary dramatically based on cancer type, severity, and evidence strength. Jury verdicts have ranged from $250,000 to $1.56 billion for individual plaintiffs. Settlement projections based on the current litigation landscape place moderate ovarian cancer claims at $50,000 to $200,000, significant claims with strong evidence at $200,000 to $1 million, and severe cases (mesothelioma, fatal cancer, wrongful death) at $1 million to $5 million or more. The Imerys Trust and direct claims against J&J may provide cumulative compensation. The MDL bellwether trials will establish clearer valuation benchmarks.

In most states, the statute of limitations for a talcum powder lawsuit starts under the "discovery rule" — when you discovered or reasonably should have discovered that your cancer was caused by or linked to talcum powder use. This is typically the date of cancer diagnosis, the date a physician explicitly linked your cancer to talc exposure, or the date you became aware of the connection through media coverage (such as the Reuters investigation) or legal advertising. The clock does not start when you first used the product, which may have been decades before your cancer developed. The specific application of the discovery rule varies by state, so consulting an attorney is essential to determine your exact deadline.

Helpful evidence includes medical records documenting your cancer diagnosis and treatment history, testimony or records confirming your use of J&J talcum powder products (purchase records, testimony from family members), records of the duration and frequency of talc use, pathology reports (some cases include findings of talc particles in ovarian tissue), testimony from treating physicians about the relationship between talc exposure and cancer, and records of the impact of cancer on your life and family. You do not need all of these — an attorney can help you identify and gather the strongest available evidence for your specific situation. Many key facts can be established through personal testimony and medical records.

J&J conducted internal testing of its talc supply, and those tests detected asbestos contamination — as documented in internal memos from the 1970s obtained through litigation discovery. However, J&J has been accused of using testing methods that were inadequate to detect low levels of asbestos contamination, and of lobbying to maintain industry testing standards that were less sensitive than available alternatives. The company publicly claimed its Baby Powder was "asbestos-free" even as its own internal records showed contamination. When the FDA conducted independent testing using more sensitive methods in 2019, it confirmed the presence of chrysotile asbestos in commercially available Baby Powder.

The cancer risk associated with talcum powder is most strongly linked to perineal (genital area) use by women, which is the pathway supported by four decades of epidemiological research on ovarian cancer. General body application of Baby Powder to infants and children has not been linked to ovarian cancer. However, any use of talc-based Baby Powder carries a theoretical risk of asbestos exposure if the product was contaminated, which could contribute to mesothelioma risk — though this risk from general body application is not well quantified. If your children used talc-based Baby Powder and have developed cancer, an attorney can evaluate whether their specific diagnosis and use pattern support a legal claim.

Yes. Wrongful death statutes of limitations vary by state, typically ranging from 1 to 3 years from the date of death. Some states measure the SOL from the date of death, while others apply a discovery rule that may start the clock when the surviving family members discovered or should have discovered that the death was caused by talcum powder. Wrongful death SOL periods are often shorter than personal injury SOL periods in the same state. Because of these tight deadlines, families who have lost a loved one to a cancer potentially linked to talcum powder should consult an attorney as soon as possible to ensure their claim is preserved.

J&J has been hit with billions of dollars in talcum powder verdicts and settlements. Major awards include the $1.56 billion Craft verdict (December 2025), the $2.12 billion Ingham verdict (reduced from $4.69 billion on appeal, 2018), the $117 million Lanzo mesothelioma verdict (2018), the $72 million Fox verdict (2016), and the $700 million consumer class action settlement (2023). J&J also contributed $505 million to the $850 million Imerys Talc Trust. However, J&J’s total talc liability remains far larger than what has been paid to date, with more than 63,000 cases still pending in the MDL and state courts. Analysts estimate J&J’s total talc exposure at tens of billions of dollars.

Mesothelioma has a very poor prognosis regardless of the exposure source. Median survival after diagnosis is 12 to 21 months, and the overall 5-year survival rate is approximately 10-15%. Pleural mesothelioma (lung lining) is the most common form, followed by peritoneal mesothelioma (abdominal lining). Treatment typically involves a combination of surgery, chemotherapy (pemetrexed + cisplatin), and radiation, but treatment is palliative in most cases. Newer immunotherapy combinations have shown some improvement in survival times. The severity and near-certain lethality of mesothelioma is a primary reason why mesothelioma talcum powder cases are typically valued higher than ovarian cancer cases in the litigation.

Epidemiological studies show a dose-response relationship — the risk of ovarian cancer increases with the frequency and duration of perineal talc use. Women who used talcum powder daily for decades have the highest risk and the strongest claims. However, even less frequent use has been associated with elevated risk in multiple studies. There is no established "safe" level of perineal talc use. The IARC’s classification of talc as Group 2A applies to all perineal talc use, not just heavy use. If you used Baby Powder or other talc products for perineal hygiene at any frequency and were diagnosed with ovarian cancer, you should consult an attorney to evaluate your potential claim.

The Imerys Talc Trust and direct claims against J&J are separate compensation pathways. The trust was created when Imerys Talc America — J&J’s primary talc supplier — emerged from Chapter 11 bankruptcy in August 2025. It contains $850 million (funded by $505 million from J&J and the remainder from Imerys) to compensate current and future talc claimants. Trust claims are processed through an administrative system with established payment criteria, typically resulting in faster but potentially lower payments than jury trials. Direct claims against J&J through the MDL or state courts preserve the right to jury trial and full verdict amounts, including punitive damages. In many cases, plaintiffs can pursue both pathways to maximize total recovery.

Even if you believe your statute of limitations may have expired, you should still consult an attorney. Several legal theories and exceptions may preserve your claim. The discovery rule may apply differently than you assume — the clock starts when you knew or should have known about the talc-cancer connection, not when you first used the product. Some states have tolling provisions that pause the SOL under certain circumstances (such as the defendant’s fraudulent concealment of known risks). Wrongful death claims may have a different SOL than personal injury claims. And some states’ consumer protection statutes have longer SOL periods than their personal injury statutes.

Compensation varies significantly based on the type and severity of cancer, the duration of talc use, and the strength of evidence. Tier I cases (moderate) with documented talc use and an ovarian cancer diagnosis may recover $50,000 to $200,000. Tier II cases (significant) with long-term documented use and comprehensive treatment records may recover $200,000 to $1 million. Tier III cases (severe) involving mesothelioma, advanced/fatal ovarian cancer, or wrongful death may recover $1 million to $5 million or more. Jury verdicts have been substantially higher — the $1.56 billion Craft verdict and $2.12 billion Ingham verdict (reduced on appeal) demonstrate the potential for exceptional awards in cases with strong evidence of J&J’s concealment.

Yes. The asbestos contamination issue is not limited to J&J products. The FDA’s expanded testing program found asbestos in cosmetic talc products from multiple brands. Talc from any mining operation where asbestos co-occurs in the geological formation carries contamination risk. However, J&J is the primary defendant in the litigation because of the extensive evidence of corporate knowledge and concealment, the massive scale of Baby Powder sales and consumer exposure, and the targeted marketing that promoted daily perineal use. If you used talc-based products from other manufacturers and developed cancer, you may still have a legal claim — an attorney can evaluate the specific products and manufacturers involved.

Yes. Shower to Shower was a talc-based body powder originally manufactured by Johnson & Johnson before being sold to Valeant Pharmaceuticals (now Bausch Health) in 2012. Shower to Shower contained the same talc ingredient as Baby Powder and is included in the talcum powder litigation. If you used Shower to Shower for perineal hygiene and were diagnosed with ovarian cancer, mesothelioma, or another cancer linked to talc, you may have a viable claim. The same evidence of J&J’s knowledge of asbestos contamination and cancer risk applies to Shower to Shower, as both products used talc from the same supply chain.

Yes. A wrongful death claim is a separate legal action from any personal injury claim your loved one could have filed during their lifetime. Even if your loved one never filed a lawsuit, never consulted an attorney, or was never aware of the connection between talcum powder and cancer, surviving family members can file a wrongful death claim. In some states, the estate may also bring a "survival action" — a claim for the deceased’s own pre-death damages (pain and suffering, medical expenses) that supplements the wrongful death claim. An attorney can evaluate both the wrongful death and survival action possibilities based on your state’s law.

It is unlikely that J&J can successfully pursue the "Texas two-step" bankruptcy strategy again. The Third Circuit’s rulings in 2023 and 2025 established clear precedent that shell entities created by solvent parent companies to absorb tort liabilities cannot file for bankruptcy in good faith. The legal landscape has also shifted, with several states passing or considering legislation to restrict divisional merger bankruptcy tactics. While J&J could theoretically attempt a different restructuring approach, the judicial precedent is firmly against the strategy. The most likely path forward is continued litigation through the MDL and state court proceedings, with potential global settlement negotiations as bellwether trial results accumulate.

Yes. Having occupational asbestos exposure does not disqualify you from pursuing a talcum powder mesothelioma claim. Mesothelioma can result from multiple sources of asbestos exposure, and you can pursue claims against all responsible parties. In fact, many mesothelioma plaintiffs file claims against multiple defendants — including employers, asbestos product manufacturers, and talcum powder companies. If you used J&J Baby Powder or Shower to Shower and were also exposed to asbestos through work, both exposures may have contributed to your disease. An experienced mesothelioma attorney can evaluate all potential sources of exposure and identify the most viable claims.

All major histological subtypes of ovarian cancer have been linked to perineal talc use in epidemiological studies, including serous, endometrioid, clear cell, and mucinous carcinomas. The strongest association has been demonstrated for serous ovarian cancer, which is the most common subtype (accounting for approximately 70% of ovarian cancers) and the most lethal. The IARC’s evaluation did not limit its Group 2A classification to any specific subtype. If you were diagnosed with any type of epithelial ovarian cancer after using talcum powder for perineal hygiene, you may have a viable claim regardless of the specific histological subtype.

Most talcum powder plaintiffs will not need to go to trial individually. The MDL process is specifically designed to resolve thousands of cases efficiently. Bellwether trials — representative cases tried before a jury — establish precedent and valuation benchmarks. These results then inform settlement negotiations for the remaining cases. Most mass tort MDLs resolve through negotiated settlements after bellwether outcomes, with individual compensation determined by a claims administration process based on each plaintiff’s specific circumstances. Some plaintiffs in state court may reach trial faster than the MDL timeline. Your attorney handles all filings and communications, and you do not need to attend court proceedings in most cases.

Filing your claim in the MDL preserves your statute of limitations from the date your case is filed. Once your case is docketed in MDL 2738 (or in a state court proceeding), the SOL is no longer an issue for that claim. This is one of the most important reasons to file promptly — even if the MDL process takes time to reach resolution, your rights are secured from the filing date. The MDL process does not change or extend your state’s statute of limitations; it simply provides a coordinated federal venue for pre-trial proceedings. If you miss your SOL deadline, you cannot later join the MDL or any settlement framework. File early to protect your rights.

Yes. Statutes of limitations vary by state, typically ranging from 2 to 5 years for personal injury claims. However, most states apply a "discovery rule" that starts the clock when you discovered (or reasonably should have discovered) that your cancer was caused by or linked to talcum powder use — not when you first used the product. For many plaintiffs, this date is the date of cancer diagnosis or the date a physician linked their cancer to talc exposure. Missouri has the longest SOL among key states at 5 years. Because the MDL is actively proceeding toward resolution, filing promptly ensures your claim is preserved and positioned for compensation.

No. Talcum powder attorneys work on a contingency fee basis, meaning they only get paid if you receive a settlement or verdict. If your case is unsuccessful, you owe nothing. The initial case evaluation is free and confidential. Attorney fees are typically 33–40% of the recovered amount, and all case costs — including medical expert fees, filing costs, and litigation expenses — are advanced by the law firm. This arrangement ensures that anyone affected by talcum powder cancer can seek legal representation regardless of their financial situation.

The cancers most strongly linked to talcum powder include ovarian cancer (the most common diagnosis in the litigation, with four decades of epidemiological evidence linking perineal talc use to elevated risk), mesothelioma (caused by asbestos contamination in talc products — a rare, aggressive, and nearly always fatal cancer of the mesothelial lining), fallopian tube cancer (related to perineal talc exposure through the same migration pathway as ovarian cancer), peritoneal cancer (cancer of the abdominal lining, associated with asbestos in talc), and endometrial cancer (emerging evidence of association with talc use). The IARC’s 2024 upgrade of talc to Group 2A ("probably carcinogenic") reflects the growing weight of evidence across multiple cancer types.

Yes. Internal J&J documents obtained through litigation discovery and later unsealed by court order reveal that the company was aware of asbestos contamination in its talc products since at least the 1970s. J&J’s own internal testing detected asbestos fibers, and company scientists and executives discussed the contamination in internal memos. Rather than reformulating, warning consumers, or withdrawing the product, J&J chose to continue selling Baby Powder, suppress unfavorable research, fight to keep damaging documents sealed in litigation, and lobby regulators to maintain favorable testing standards. Reuters’ December 2018 investigation titled "J&J Knew" documented this pattern of concealment in detail. The evidence of J&J’s knowledge is the primary basis for the massive punitive damage awards juries have returned.

In October 2021, J&J executed a "Texas two-step" bankruptcy strategy: it created a subsidiary called LTL Management LLC, transferred all talc liabilities to this shell entity, and filed LTL for Chapter 11 bankruptcy to cap its talc exposure at $8.9 billion. The Third Circuit Court of Appeals rejected LTL’s bankruptcy petition twice — first in January 2023 and again in 2025 — finding that the filing was not in good faith because LTL was not in financial distress. The court noted that J&J, a company with approximately $400 billion in market capitalization, created the entity solely to shield itself from legitimate tort claims. The failure of the bankruptcy strategy means all pending talcum powder lawsuits will proceed through the traditional litigation process, preserving plaintiffs’ right to individual verdicts and uncapped settlements.

Families filing talcum powder lawsuits may recover several categories of damages. Compensatory damages cover direct costs including medical expenses (surgery, chemotherapy, radiation, hospitalizations, medications, follow-up care), lost wages and earning capacity during treatment and recovery, and out-of-pocket costs related to cancer diagnosis and treatment. Non-economic damages compensate for pain and suffering, emotional distress, loss of quality of life, loss of consortium (impact on spousal relationship), and disfigurement from surgical procedures. Punitive damages are a critical component of talcum powder verdicts. Because juries have found that J&J knew its products were dangerous and concealed this information for decades, punitive damage awards have been substantial — $1 billion in the Craft verdict and $4.14 billion in the Ingham verdict (reduced on appeal). Punitive damages are designed to punish willful and reckless corporate conduct and deter future misconduct. Wrongful death damages may include funeral and burial expenses, loss of financial support, loss of companionship and guidance, and pre-death pain and suffering of the deceased.

The timeline for talcum powder lawsuits varies depending on whether your case is in the federal MDL or state court proceedings. The MDL 2738 in the District of New Jersey is actively proceeding with bellwether trials — the first federal bellwether, Judkins v. J&J, is scheduled for early 2026. Bellwether results typically establish valuation benchmarks that inform settlement negotiations for the remaining cases. Individual settlement timelines generally range from 1 to 3 years after bellwether outcomes. State court cases may proceed on independent timelines, and some state courts (particularly St. Louis and Philadelphia) have produced faster results than the federal MDL. The Imerys Talc Trust ($850 million) provides an additional avenue for compensation that may distribute payments on a separate timeline. Your attorney can advise on the expected timeline for your specific case based on the venue, the strength of your evidence, and the current status of proceedings. Contingency fee arrangements mean fees are typically owed only from any recovery.

Yes. Surviving family members can file wrongful death claims on behalf of loved ones who died from ovarian cancer, mesothelioma, or other cancers linked to talcum powder use. Wrongful death claims are a significant component of the talcum powder litigation, as many plaintiffs were diagnosed with advanced or fatal cancers. Several of the largest talc verdicts — including the $72 million Fox verdict in St. Louis — were wrongful death cases. Wrongful death claims may recover damages including funeral and burial expenses, loss of financial support the deceased would have provided, loss of companionship, guidance, and consortium, medical expenses incurred before death, and the pain and suffering the deceased experienced before passing. The statute of limitations for wrongful death claims varies by state and is typically measured from the date of death, with a discovery rule that may apply. If a loved one died from a cancer potentially linked to talcum powder use, consulting an attorney promptly is critical to preserving the claim.

Cornstarch-based baby powder is generally considered a safer alternative to talc-based products. Cornstarch does not carry the asbestos contamination risk associated with talc mining, and there is no established epidemiological link between cornstarch and ovarian cancer. J&J itself replaced talc-based Baby Powder with a cornstarch formula when it discontinued the talc version in North America (May 2020) and globally (August 2022). However, the switch to cornstarch does not address harm already caused by decades of talc-based product use. If you used talc-based Baby Powder or Shower to Shower in the past and have been diagnosed with ovarian cancer or mesothelioma, the fact that J&J now sells a cornstarch version does not affect your legal claim. Your claim is based on the talc-based product you used and the harm it caused. The product reformulation actually strengthens plaintiffs’ cases by implicitly acknowledging that the talc-based formula was problematic.